FDA’s Center for Drug Evaluation and Research (CDER) approved 46 new drugs in 2017, more than doubling the number of novel medications approved in 2016.
Among the drugs that have been recently launched or will be launched soon, Dupixent, Ocrevus and Imfinizi top the most promising drugs in 2018, according to IgeaHub, a pharmaceutical club for industry influencers.
The revenues of Dupixent, a prescription drug used to treat patients with uncontrolled eczema, and Ocrevus, a treatment for people with multiple sclerosis, are each projected to reach $4 billion by 2022. Immunotherapy drug Imfinzi’s revenue is expected to yield $4 billion by 2023.
The top 10 list also include Ozempic, Zejula, Hemlibra, Tremfya, Kisqali, Nerlynx and Verzenio. Four of the drugs are related to treatments for oncology. The projected revenue combined for the top 10 promising drugs could reach more than $24 billion by 2023.
Subscribe to the MMIT blog for more insights on trends affecting pharmaceutical manufacturers, providers and payers.